RECALLS AND SAFETY ALERTS RISK MANAGEMENT PROGRAM FOR PROCRIT, EPOGEN AND ARANESP
May 7, 2010
FDA is requiring that Erythropoiesis-Stimulating Agents (ESAs) be prescribed and used under a special risk management program. This program is designed to inform healthcare providers and their patients about the risks of these drugs and to ensure tha...
Full Story Below
Rapid Response
Free Case Evaluation
The Help You Need,
When You Need it Most
More from FDA News Directory
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
